Drug Profile
Levodropropizine controlled-release - Korea United Pharm
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Korea United Pharm Inc
- Class Antitussives; Small molecules
- Mechanism of Action Neuropeptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cough
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in Cough(In volunteers) in South Korea (PO, Controlled release)
- 29 Jun 2012 Phase-I clinical trials in Cough (In volunteers) in South Korea (PO) (KCT0002383)